Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.

Bonilla-Martinez ZL, Albrecht J, Troxel AB, Taylor L, Okawa J, Dulay S, Werth VP.

Arch Dermatol. 2008 Feb;144(2):173-80. doi: 10.1001/archderm.144.2.173.

2.

Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.

Jolly M, Kazmi N, Mikolaitis RA, Sequeira W, Block JA.

J Am Acad Dermatol. 2013 Apr;68(4):618-23. doi: 10.1016/j.jaad.2012.08.035. Epub 2012 Oct 26.

PMID:
23107310
3.

Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI.

Bein D, Kuehn E, Meuth AM, Amler S, Haust M, Nyberg F, Sauerland C, Luger TA, Bonsmann G, Kuhn A.

J Eur Acad Dermatol Venereol. 2011 Jun;25(6):652-9. doi: 10.1111/j.1468-3083.2010.03844.x. Epub 2010 Sep 16.

PMID:
20849444
4.

The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.

Salphale P, Danda D, Chandrashekar L, Peter D, Jayaseeli N, George R.

Lupus. 2011 Dec;20(14):1510-7. doi: 10.1177/0961203311418789. Epub 2011 Oct 13.

PMID:
21997966
5.

The impact of skin damage due to cutaneous lupus on quality of life.

Verma SM, Okawa J, Propert KJ, Werth VP.

Br J Dermatol. 2014 Feb;170(2):315-21. doi: 10.1111/bjd.12653.

6.

Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.

Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, Troxel AB, Werth VP.

Arch Dermatol. 2011 Feb;147(2):203-8. doi: 10.1001/archdermatol.2010.435.

7.

Characterization of clinical photosensitivity in cutaneous lupus erythematosus.

Foering K, Chang AY, Piette EW, Cucchiara A, Okawa J, Werth VP.

J Am Acad Dermatol. 2013 Aug;69(2):205-13. doi: 10.1016/j.jaad.2013.03.015. Epub 2013 May 3.

8.

Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).

Yokogawa N, Tanikawa A, Amagai M, Kato Y, Momose Y, Arai S, Eto H, Ikeda T, Furukawa F.

Mod Rheumatol. 2013 Mar;23(2):318-22. doi: 10.1007/s10165-012-0656-3. Epub 2012 May 12. Erratum in: Mod Rheumatol. 2014 Jul;24(4):701.

PMID:
22581095
9.

Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).

Yokogawa N, Kato Y, Sugii S, Inada S.

Mod Rheumatol. 2012 Apr;22(2):249-55. doi: 10.1007/s10165-011-0503-y. Epub 2011 Aug 14.

PMID:
21842436
10.

Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus.

Kuhn A, Meuth AM, Bein D, Amler S, Beissert S, Böhm M, Brehler R, Ehrchen J, Grundmann S, Haust M, Ruland V, Schiller M, Schulz P, Ständer S, Sauerland C, Köpcke W, Luger TA, Bonsmann G.

Br J Dermatol. 2010 Jul;163(1):83-92. doi: 10.1111/j.1365-2133.2010.09799.x. Epub 2010 Apr 12. Erratum in: Br J Dermatol. 2010 Oct;163(4):898. Meuth, A M [added]; Bein, D [added]; Köpcke, W [added].

PMID:
20394621
11.

Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity.

Méndez-Flores S, Orozco-Topete R, Bermúdez-Bermejo P, Hernández-Molina G.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):940-2. Epub 2013 Aug 2.

PMID:
23981524
12.

Clinical outcome measures for cutaneous lupus erythematosus.

Albrecht J, Werth VP.

Lupus. 2010 Aug;19(9):1137-43. doi: 10.1177/0961203310370049. Review.

13.

Impact of smoking in cutaneous lupus erythematosus.

Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, Werth VP.

Arch Dermatol. 2012 Mar;148(3):317-22. doi: 10.1001/archdermatol.2011.342. Epub 2011 Nov 21. Erratum in: Arch Dermatol. 2012 Dec;148(12):1369.

14.

The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology.

Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL, Kovarik C, Kwan-Morley J, Okawa J, Propert K, Rogers N, Rose M, Thomas P, Troxel AB, Van Voorhees A, Feldt JV, Weber AL, Werth VP.

Arthritis Rheum. 2008 Mar 15;59(3):338-44. doi: 10.1002/art.23319.

15.

Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.

Sigges J, Biazar C, Landmann A, Ruland V, Patsinakidis N, Amler S, Bonsmann G, Kuhn A; EUSCLE Co-Authors..

Autoimmun Rev. 2013 May;12(7):694-702. doi: 10.1016/j.autrev.2012.10.005. Epub 2012 Dec 5. Review.

PMID:
23220353
16.
17.

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP.

J Invest Dermatol. 2005 Nov;125(5):889-94.

18.

Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.

Kuhn A, Sigges J, Biazar C, Ruland V, Patsinakidis N, Landmann A, Amler S, Bonsmann G; EUSCLE coauthors..

Br J Dermatol. 2014 Sep;171(3):571-9. doi: 10.1111/bjd.13006. Epub 2014 Aug 25.

PMID:
24673427
19.

Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.

Moghadam-Kia S, Chilek K, Gaines E, Costner M, Rose ME, Okawa J, Werth VP.

Arch Dermatol. 2009 Mar;145(3):255-60. doi: 10.1001/archdermatol.2008.594.

20.

Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus.

Albrecht J, Werth VP.

Dermatol Ther. 2007 Mar-Apr;20(2):93-101.

PMID:
17537137

Supplemental Content

Support Center